Proteomics analysis of malignant pericardial effusion and determine the profile of malignancy-associated protein

Year 2015, Volume: 5 Issue: 1, 43 - 52, 07.09.2015

Sabiye Yılmaz Murat Kasap Dilek Ural Hüseyin Gündüz

https://doi.org/10.5505/sakaryamj.2015.17894

Abstract

Objective: We want to analyse protein content by proteomics of pericardial effusion due to lung cancer, finding new biomarker and overview of proteomics studies.Methods: 5 patients (4 adenocarcinoma, one large cell), 5 control (CABC applied) pericardial effusion were included in the study. The mean age of patients group 47.4 ± 7.92 with 5 men; the mean age of the control group 63.4 ± 7.7 with 4 men, consisted of one lady. Specimens were keeped at -80ºC. 2-D gel electrophoresis of proteins based on isoelectric points and molecular weights. Obtained gels were stained with Coomasia stain and protein spots displayed. Image analyses were made by Melanie Viewer program. Protein spots were evaluated visually. Upregulation and downregulation proteins were evaluated. We don\'t have data analyse method for protein description, proteins weren\'t identification. Ptotein spots were marked with Melanie 7 program,they were compared with each other and normal human plasma protein spots according to the molecular weights.Results: We found much more protein in malign pericardial effusion.These proteins were similar to serum plasma proteins. Identified proteins mayn't be new biomarker,also these proteins weren't founded in CAD. Because of this it can be guide for medication thearpy. We didn't entitle proteins but these datas strenghten protein proteomics analyses in malign pericardial effusions.Conclusion: Proteins secreted by tumor cells display tumor load, response to treatment and can be used for diagnosis, treatment modalities, prognosis analysis. Developments increase in proteomics field and much more strong data analyse programs were improved. With these improvements more sensitive and specific protein biomarkers can be discovered.

Keywords

Proteomics, pericardial effusion; malignancy; biomarkers; cardiovascular diseases and proteomics

Malign Perikard efüzyonunda Proteomiks analizi ve malignite ilişkili protein profilinin belirlenmesi

Abstract

Amaç: Akciğer kanserine bağlı perikard efüzyonunda protein içeriğinin proteomiks analizi,ilişkili olabilecek yeni biyobelirteçlerin araştırılması ve proteomiks çalışmalarına genel bakış.Yöntemler: 5 hasta (4 adenokarsinom, 1 büyük hücreli), 5 kontrol (CABC uygulanan) perikard efüzyonu çalışmaya dahil edildi. Hasta grubu yaş ortalaması 47,4±7,92 olan 5 erkekten; kontrol grubu yaş ortalaması 63,4±7.7 olan 4 erkek, 1 bayandan oluşmaktaydı. Örnekler -80ºC'de saklandı. 2-D jel elektroforezinde proteinler izoelektrik noktalarına ve moleküler ağırlıklarına göre ayrıldı. Elde edilen jeller Coomasia boyası ile boyanarak protein spotları açığa çıkarıldı. Görüntü analizi Melanie 7 Viewer programı ile yapıldı. Protein spotları öncelikle görsel olarak değerlendirildi, upregülasyona veya downregülasyona uğrayan proteinler saptandı. Proteinlerin tanımlanabilmesi için data analiz metodu halihazırda bulunmadığından proteinler tanımlanamadı. Ancak Melanie 7 programı ile her bir jeldeki protein spotları işaretlendi, birbirleriyle ve normal insan plazmasının 2-D jelindeki protein spotları ile moleküler ağırlıklarına göre karşılaştırıldı.Bulgular: Malign efüzyonlarda daha fazla proteinin salındığı, plazma ve serumda bulunan proteinlerle benzer olduğu görüldü. Saptanan proteinlerin yeni bir biyobelirteç olma olasılığının düşük olmasına rağmen KAH grubunda olmaması malin efüzyonlarda hedef molekül olarak olası ilaç tedavisi için yol gösterici olabilirdi. Çalışmada proteinlerin isimlendirilmesi yapılamamış, fonksiyon ve varlığı ile ilgili net bir karar birliğine varılamamış olsa da bu veriler malign perikardiyal efüzyonlarda proteomiks analizinin genişletilerek devam edilmesini destekler.Sonuç: Tümör hücrelerinin salgıladığı proteinler tümör yükünü, tedaviye verdiği cevabı gösterebilir ve gelecekte güçlü, ümit verici tümör belirteçi olabilir. Tanı, tedavinin belirlenmesi ve prognoz tayininde kullunılabilinir. Proteomiks alanında her geçen gün gelişmeler artmaktadır, daha güçlü data analiz programları geliştirilmektedir. Gelecekte sensitivitesi ve spesifisitesi artmış protein biyobelirteçleri bulunabilecektir.

Keywords

Proteomiks, perikard efüzyonu; malignite; biyobelirteç; kardiyovasküler hastalıklar ve proteomiks

References

• 1. Little WC, Freeman GL. Pericardial disease. Circulation 2006; 113:1622-32.
• 2. Maisch B, Seferovi� PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; the Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2004; 25:587-610.
• 3. Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Cancer 1995; 76:1377-87
• 4. Girardi LN, Ginsberg RJ, Burt ME. Pericardiocentesis and intrapericardial sclerosis: effective theraphy for malignant pericardial effusions. Ann Thorac Surg 1997; 64:1422-7.
• 5. Martinoni A, Cipolla CM, Civelli M, Cardinale D, Lamantia G, Colleoni M, DeBraud F, Susini G, Martinelli G, Goldhirsh A, Fiorentini C. Intrapericardial treatment of neoplastic pericardial effusions. Herz 2000; 25:787-93.
• 6. Spodick D H. The Pericardium: A Comprehensive Textbook. Marcel Dekker, New York, NY 1997.
• 7. Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A, Risberg B, Johansen P. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001; 25:1405-12.
• 8. Chapman K. The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans 2002; 30:827.
• 9. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of Cell. 4th ed. New York: Garland Science, 2002.
• 10. Washburn MP, Wolters D, Yates JR 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19:242-7.
• 11. Weber K, Pringle JR, Osborn M. Measurement of molecular weights by electrophoresis on SDS-acrylamide gel. Methods Enzymol 1972; 26:3-27.
• 12. Marko-Varga G. Proteomics principles and Challenges. Pure Appl Chem 2004; 76:829-837.
• 13. Biberoğlu G. Kütle Spektrometresi ve Tıp Alanında Kullanımı. T Klin J Med Sci 2003; 23:491-498.
• 14. Moore CA, Khoury MJ, Bradley LA. From genetics to genomics using gene-based medicine to prevent disease and promote health in children. Semin Perinatol 2005; 29:135-43.
• 15. Kotyza J, Pesek M, Puzman P, Havel D. Progelatinase B/ matrix metalloproteinase-9 proenzyme as a marker of pleural inflammation. Exp Lung Res 2004; 30:297-309.
• 16. Salomaa ER, Viander M, Saaresranta T, Terho EO. Complement components and their activation products in pleural fluid. Chest 1998; 114:723-30.
• 17. Hung TL, Chen FF, Liu JM, Lai WW, Hsiao AL, Huang WT, Chen HH, Su WC. Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis. Clin Cancer Res 2003; 9:2605-12.
• 18. Hsieh WY, Chen MW, Ho HT, You TM, Lu YT. Identification of differentially expressed proteins in human malignant pleural effusions. Eur Respir J 2000; 28:1178-85.
• 19. Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, van Meerbeeck JP, Burgers SA, Hoogsteden HC, Lambrecht BN. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol 2004; 31:114-21.
• 20. Shijubo N, Honda Y, Fujishima T, Takahashi H, Kodama T, Kuroki Y, Akino T, Abe S. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma. Eur Respir J 1995; 8:403-6.
• 21. Garcia-Pachon E, Soler MJ, Padilla-Navas I, Romero V, Shum C. C-reactive protein in lymphocytic pleural effusions: a diagnostic aid in tuberculous pleuritis. Respiration 2005; 72:486-9.
• 22. Tyers M, Mann M. From genomics to proteomics. Nature 2003; 422:193-7.
• 23. Fujii K, Nakano T, Kawamura T, Usui F, Bando Y, Wang R, Nishimura T. Multidimensional protein profiling technology and its application to human plasma proteome. J Proteome Res 2004; 3:712-8.
• 24. Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004; 363:717-27.
• 25. Fujita M, Komeda M, Hasegawa K, Kihara Y, Nohara R, Sasayama S. Pericardial fluid as a new material for clinical heart research. Int J Cardiol 2001; 77:113-8.
• 26. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110:2168-74.
• 27. Oyama J, Shimokawa H, Morita S, Yasui H, Takeshita A. Elevated interleukin-1beta in pericardial fluid of patients with ischemic heart disease. Coron Artery Dis 2001; 12:567-71.
• 28. Tambara K, Fujita M, Miyamoto S, Doi K, Nishimura K, Komeda M. Pericardial fluid level of heart-type cytoplasmic fatty acid-binding protein (H-FABP) is an indicator of severe myocardial ischemia. Int J Cardiol 2004; 93:281-4.
• 29. Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W. CA 125 and its relation to cardiac function. Am Heart J 1999; 137:1044-9